Bone Therapeutics’ allogeneic cell therapy product, ALLOB, meets primary endpoints in Phase IIa study in patients undergoing a lumbar spinal fusion procedure

    NEXT STORY
    Oncology Venture increases its ownership in dovitinib
    PREV STORY
    The Three Strategies of Individual Patient Engagement
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    An Urgent Ask During #GIVINGTUESDAY for Our Police Who Suffer From PTSD

    author_avatar
    NASDAQ Market News

    Adaptive Biotechnologies Receives New York State CLEP Approval for clonoSEQ to Detect and Monitor Minimal Residual Disease (MRD) in Patients with Certain Blood Cancers

    author_avatar
    NASDAQ Market News

    PositiveID’s ExcitePCR Subsidiary to Hold Press Conference Announcing Lawrence Livermore National Report on its FireflyDX

    DELRAY BEACH, Fla., Sept. 12, 2017 (GLOBE NEWSWIRE) -- PositiveID Corporation's (OTCQB:PSID) ExcitePCR subsidiary today ...

    author_avatar
    NASDAQ Market News